Monoclonal Antibody Development Targeting IL-1R for Autoimmune Diseases

With the discovery of new targets in autoimmune diseases (ADs), the development of monoclonal antibody (mAb) drugs will become a hot field. Competitiveness and market proportion of mAb will further expand. With extensive experience in the development of mAb, Creative Biolabs provides comprehensive mAb development services, such as mAb targeting interleukin-1 receptor (IL-1R) for the treatment of ADs.

Introduction of Interleukin-1 Family (IL-1F) and IL-1F Receptors

IL-1F encompasses eleven proteins, which share a similar structure, a non-conventional secretion mode and a similar receptor binding mode. They are involved in different aspects of systemic and local inflammation. Many IL-1F cytokines act as extracellular soluble factors that bind to cognate receptors on the membrane of target cells. IL-1F receptors share a similar structure that includes an extracellular moiety formed by three immunoglobulin (Ig)-like domains, a transmembrane domain, and an intracellular portion containing a Toll-IL-1-receptor (TIR) sequence responsible for signaling.

Fig.1 IL-1 cytokine subfamilies and receptors. (Dinarello, 2019)

IL-1 and Autoimmune Disease

IL-1β is the most frequently studied member of the IL-1 family, with properties that are relevant to several rheumatic diseases. A study found that IL-1 plays a role in the progression of atherosclerosis and cardiac remodeling and is an important mediator in the loss of beta cells. Another study showed that IL-1β is recognized to play an important role in experimental autoimmune encephalomyelitis (EAE) and perhaps multiple sclerosis (MS). The fact that clinical EAE is significantly attenuated in IL-1R-deficient and IL-1β-deficient mice are observed by scientists. At the same time, IL-1β is also found in the blood, cerebrospinal fluid, and central nervous system (CNS) lesions of MS patients.

Monoclonal Antibody Development Targeting IL-1R

According to the latest consultation, IL-1 signaling plays an important role in ADs. For example, IL-1R signaling blockade ameliorates EAE severity and/or delays disease onset. Therefore, the therapeutic strategy of inhibiting IL-1R signaling is considered a new way to treat autoimmune diseases, especially for MS. To block the signal pathway and advance the treatment of ADs, our company uses advanced platforms to explore the signal transduction process. We are committed to providing a range of mAb development services to advance the therapy of ADs.

Creative Biolabs is a leader in the field of mAb development. We offer a range of mAb development services for the research of ADs. We have finished many projects for companies, universities, and scientific research institutes all over the world. Our professional scientists help you succeed early. If you are interested in our services, please contact us.

Reference

1. Dinarello, C.A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nature Reviews Rheumatology. 2019, 15(10): 612-632.

For Research Use Only | Not For Clinical Use